Media headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1409048476544 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Fate Therapeutics (FATE) Expected to Announce Earnings of -$0.22 Per Share (americanbankingnews.com)
- Fate Therapeutics (FATE) Lifted to Buy at ValuEngine (americanbankingnews.com)
- Wired News – Fate Therapeutics Presented Positive Clinical Data of FATE-NK100’s APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018 (finance.yahoo.com)
- 3 Things In Biotech, April 1: Fate’s Omens, Mallinckrodt’s Trial, Insmed’s Journey (seekingalpha.com)
- Fate Therapeutics’ (FATE) Buy Rating Reiterated at BMO Capital Markets (americanbankingnews.com)
Fate Therapeutics stock traded down $0.54 during mid-day trading on Thursday, hitting $9.97. 408,662 shares of the company’s stock traded hands, compared to its average volume of 749,592. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $14.45. The company has a market capitalization of $507.67, a price-to-earnings ratio of -9.77 and a beta of 1.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29.
Several research firms have recently commented on FATE. UBS downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 6th. HC Wainwright downgraded Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price objective for the company. in a report on Tuesday, March 6th. Wells Fargo reissued an “outperform” rating and issued a $19.00 price objective (up previously from $10.00) on shares of Fate Therapeutics in a report on Tuesday, March 6th. BMO Capital Markets raised their price target on Fate Therapeutics from $7.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $10.00 price target (down previously from $19.00) on shares of Fate Therapeutics in a report on Tuesday, March 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Fate Therapeutics currently has an average rating of “Buy” and an average price target of $15.00.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.